Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.

Šiarnik P, Rádiková Ž, Kollár B, Kutšálová M, Penesová A, Havranová A, Imrich R, Vlček M, Žitňanová I, Krastev G, Turčáni P

Neurology and therapy20 Jun 2026

PMID42321509PMCIDPMC13396319DOI10.1007/s40120-026-00982-4PepBankPUB-42321509

Read at source PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide produced no significant plasma NfL difference versus control.
In plain wordsIn people with RRMS receiving natalizumab, dulaglutide did not significantly change plasma NfL compared with control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePlasma NfL
Study
n = 28
Comparator
no adjunctive therapy
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
However, no significant between-group differences were observed in plasma NfL, brain MRI volumetric measures, or cognitive performance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150910
02HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide produced no significant brain MRI volumetric difference versus control.
In plain wordsIn people with RRMS receiving natalizumab, dulaglutide did not significantly change brain volume measures compared with control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBrain MRI volumetry
Study
n = 28
Comparator
no adjunctive therapy
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
However, no significant between-group differences were observed in plasma NfL, brain MRI volumetric measures, or cognitive performance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150911
03HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide produced no significant cognitive performance difference versus control.
In plain wordsIn people with RRMS receiving natalizumab, dulaglutide did not significantly change cognitive performance compared with control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeCognitive performance
Study
n = 28
Comparator
no adjunctive therapy
Analysis
Secondary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
However, no significant between-group differences were observed in plasma NfL, brain MRI volumetric measures, or cognitive performance.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150912
04HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide significantly reduced weight.
In plain wordsIn people with RRMS receiving natalizumab, adjunctive dulaglutide significantly reduced weight.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWeight
Study
n = 15
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly reduced weight, body mass index (BMI), body fat, and visceral fat, and improved glucose tolerance (reduced glucose area under the curve [AUC]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150901
05HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide significantly reduced BMI.
In plain wordsIn people with RRMS receiving natalizumab, adjunctive dulaglutide significantly reduced BMI.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBMI
Study
n = 15
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly reduced weight, body mass index (BMI), body fat, and visceral fat, and improved glucose tolerance (reduced glucose area under the curve [AUC]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150902
06HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide significantly reduced body fat.
In plain wordsIn people with RRMS receiving natalizumab, adjunctive dulaglutide significantly reduced body fat.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody fat
Study
n = 15
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly reduced weight, body mass index (BMI), body fat, and visceral fat, and improved glucose tolerance (reduced glucose area under the curve [AUC]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150903
07HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide significantly reduced visceral fat.
In plain wordsIn people with RRMS receiving natalizumab, adjunctive dulaglutide significantly reduced visceral fat.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseVisceral fat
Study
n = 15
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly reduced weight, body mass index (BMI), body fat, and visceral fat, and improved glucose tolerance (reduced glucose area under the curve [AUC]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150904
08HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, adjunctive dulaglutide improved glucose tolerance through reduced glucose AUC.
In plain wordsIn people with RRMS receiving natalizumab, adjunctive dulaglutide reduced glucose exposure during tolerance testing.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGlucose AUC
Study
n = 15
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Dulaglutide significantly reduced weight, body mass index (BMI), body fat, and visceral fat, and improved glucose tolerance (reduced glucose area under the curve [AUC]).
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150905
09HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, exploratory analysis indicated a trend toward improved walking speed with dulaglutide.
In plain wordsIn people with RRMS receiving natalizumab, exploratory analysis suggested improved walking speed with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseWalking speed
Study
n = 28
Comparator
no adjunctive therapy
Analysis
Exploratory
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Exploratory analyses indicated trends toward improved walking speed (T25FW, group × time interaction: F_1,26 = 9.4, p = 0.005) and non-dominant hand manual dexterity (9HPT, F_1,26 = 4.7, p = 0.039) in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150908
10HumanRandomized controlled trialEfficacy outcome
In natalizumab-treated RRMS, exploratory analysis indicated a trend toward improved non-dominant hand dexterity with dulaglutide.
In plain wordsIn people with RRMS receiving natalizumab, exploratory analysis suggested improved non-dominant hand dexterity with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNon-dominant hand dexterity
Study
n = 28
Comparator
no adjunctive therapy
Analysis
Exploratory
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
0.75 mg once weekly · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Exploratory analyses indicated trends toward improved walking speed (T25FW, group × time interaction: F_1,26 = 9.4, p = 0.005) and non-dominant hand manual dexterity (9HPT, F_1,26 = 4.7, p = 0.039) in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
Report a problemFND-4232150909

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

11HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In natalizumab-treated RRMS, no adverse events occurred in either trial group, including adjunctive dulaglutide.
In plain wordsNo adverse events occurred in either RRMS trial group, including adjunctive dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAdverse events
Study
n = 28
Comparator
no adjunctive therapy
Outcome group
Adverse events · Whole body
Source sentences
Summary
No adverse events were recorded in either group; no discontinuations occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4232150906
12HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In natalizumab-treated RRMS, no discontinuations occurred, including with adjunctive dulaglutide.
In plain wordsNo discontinuations occurred in the RRMS trial, including with adjunctive dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiscontinuations
Study
n = 28
Comparator
no adjunctive therapy
Outcome group
Adverse events · Whole body
Source sentences
Summary
No adverse events were recorded in either group; no discontinuations occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
In this prospective, randomized, open-label, single-center proof-of-concept study, 28 patients with RRMS receiving stable natalizumab treatment were randomized to adjunctive GLP-1RA (dulaglutide; 0.75 mg subcutaneously once weekly for 12 months; n = 15) or to a control group without adjunctive therapy (n = 13).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4232150907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.